Oclacitinib maleate - CAS 1208319-27-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C19H27N5O6S
Molecular Weight:
453.51
COA:
Inquire
Targets:
JAK
Description:
Oclacitinib maleate was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
(Z)-but-2-enedioic acid;N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl]methanesulfonamide; Oclacitinib (maleate)
Solubility:
DMSO: ≥ 100 mg/mL
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
InChIKey:
VQIGDTLRBSNOBV-BTJKTKAUSA-N
InChI:
1S/C15H23N5O2S.C4H4O4/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15;5-3(6)1-2-4(7)8/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19);1-2H,(H,5,6)(H,7,8)/b;2-1-
Canonical SMILES:
CNS(=O)(=O)CC1CCC(CC1)N(C)C2=NC=NC3=C2C=CN3.C(=CC(=O)O)C(=O)O
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related JAK Products


Itacitinib
(CAS: 1334298-90-6)

Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of crea...

CAS 1092578-46-5 (3R,4S)-Tofacitinib

(3R,4S)-Tofacitinib
(CAS: 1092578-46-5)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

CAS 1092578-47-6 (3S,4S)-Tofacitinib

(3S,4S)-Tofacitinib
(CAS: 1092578-47-6)

Tofacitinib is a novel inhibitor of JAK3 with IC50 of 1 nM, 20- to 100-fold less potent against JAK2 and JAK1.

CAS 1021868-92-7 ZM 39923 HCl

ZM 39923 HCl
(CAS: 1021868-92-7)

Selective inhibitor of Janus tyrosine kinase 3 (JAK3). pIC50 values are 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Breaks down in neut...

CAS 540737-29-9 Tofacitinib Citrate

Tofacitinib Citrate
(CAS: 540737-29-9)

Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rh...

CAS 211555-05-4 WHI-P97

WHI-P97
(CAS: 211555-05-4)

WHI-P97 is a potent cell-permeable and specific inhibitor of JAK3(IC50 = 11 μM). Inhibits JAK3 in immune complex kinase assaysin a dose-dependent fashion and re...

CAS 1895895-38-1 CHZ868

CHZ868
(CAS: 1895895-38-1)

CHZ868 is a potent and selective type II JAK2 inhibitor (IC50= 0.17 μM in EPOR JAK2 WT Ba/F3 cell). CHZ868 potently inhibited proliferation of cells expressing ...

CAS 1092939-16-6 Ruxolitinib sulfate

Ruxolitinib sulfate
(CAS: 1092939-16-6)

Ruxolitinib sulfate (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1...

CAS 1056636-07-7 CYT387 Mesylate

CYT387 Mesylate
(CAS: 1056636-07-7)

CYT387 Mesylate is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.

CAS 273727-89-2 ZM 39923

ZM 39923
(CAS: 273727-89-2)

ZM 39923 inhibits Janus kinase (IC50=10 nM).

CAS 202475-60-3 JANEX-1

JANEX-1
(CAS: 202475-60-3)

A cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (Janus family kinase 3; IC50 = 78 µM). Has no effect on JAK1, JAK2, or Zap...

NS-018
(CAS: 1239358-86-1)

NS-018, a selective JAK2 as well as Src family tyrosine kinases inhibitor that could probably induce the apoptosis of tumor cells. It is still under Phase I/II ...

CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

Upadacitinib
(CAS: 1310726-60-3)

Upadacitinib is a selective JAK inhibitor under the development of AbbVie.ABT-494 is nearly 74 fold selective for Jak1 over Jak2 in cellular assays dependent on...

CAS 1187594-09-7 Baricitinib

Baricitinib
(CAS: 1187594-09-7)

Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK...

CAS 1092939-17-7 Ruxolitinib phosphate

Ruxolitinib phosphate
(CAS: 1092939-17-7)

Ruxolitinib phosphate is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus J...

CAS 1206163-45-2 Solcitinib

Solcitinib
(CAS: 1206163-45-2)

Solcitinib, also known as GSK2586184 or GLPG0778, is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis, systemic ...

CP-690550A
(CAS: 1243290-37-0)

This active molecular is a novel Janus Kinase 3 (JAK3) inhibitor. CP-690550A is an immunosuppressant for the treatment of rheumatoid arthritis, psoriasis, trans...

CAS 935666-88-9 AZD-1480

AZD-1480
(CAS: 935666-88-9)

AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. AZD1480 inhibits JAK2 activation, leadin...

BBT594
(CAS: 882405-89-2)

BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently ...

Chemical Structure

CAS 1208319-27-0 Oclacitinib maleate

Quick Inquiry

Verification code

Featured Items